APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Asthma and COPD

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Asthma and COPD Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchDrugs for Asthma and COPD Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Asthma and COPD Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Drugs for Asthma and COPD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Asthma and COPD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Asthma and COPD Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for Asthma and COPD market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs for Asthma and COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Asthma and COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Asthma and COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Asthma and COPD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs for Asthma and COPD include GSK, Teva, Novartis, Merck, Mylan, Roche, AstraZeneca, Vertex and Sumitomo Dainippon, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs for Asthma and COPD, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Asthma and COPD, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Asthma and COPD, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Asthma and COPD revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Asthma and COPD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Asthma and COPD revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Asthma and COPD Segment by Company

GSK

Teva

Novartis

Merck

Mylan

Roche

AstraZeneca

Vertex

Sumitomo Dainippon

Chiesi

Boehringer Ingelheim

Beximco

Drugs for Asthma and COPD Segment by Type

Inhalable & Nasal Spray

Oral

Others

Drugs for Asthma and COPD Segment by Application

Asthma

COPD

Drugs for Asthma and COPD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Asthma and COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Asthma and COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Asthma and COPD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Asthma and COPD in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Asthma and COPD company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Asthma and COPD revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Asthma and COPD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Inhalable & Nasal Spray Major Player Table 3. Oral Major Player Table 4. Others Major Player Table 5. Global Drugs for Asthma and COPD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Asthma Major Player Table 7. COPD Major Player Table 8. Drugs for Asthma and COPD Industry Trends Table 9. Drugs for Asthma and COPD Industry Drivers Table 10. Drugs for Asthma and COPD Industry Opportunities and Challenges Table 11. Drugs for Asthma and COPD Industry Restraints Table 12. Global Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Drugs for Asthma and COPD Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Drugs for Asthma and COPD Market Share by Region (2021-2026) Table 15. Global Drugs for Asthma and COPD Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Drugs for Asthma and COPD Market Share by Region (2027-2032) Table 17. Global Drugs for Asthma and COPD Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Drugs for Asthma and COPD Revenue Market Share by Players (2021-2026) Table 19. Global Drugs for Asthma and COPD Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Drugs for Asthma and COPD Key Players Headquarters & Area Served Table 21. Global Drugs for Asthma and COPD Players, Product Type & Application Table 22. Global Drugs for Asthma and COPD Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Drugs for Asthma and COPD by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Drugs for Asthma and COPD Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Asthma and COPD Revenue Market Share by Type (2021-2026) Table 29. Global Drugs for Asthma and COPD Revenue Market Share by Type (2027-2032) Table 30. Global Drugs for Asthma and COPD Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Drugs for Asthma and COPD Revenue Market Share by Application (2021-2026) Table 34. Global Drugs for Asthma and COPD Revenue Market Share by Application (2027-2032) Table 35. GSK Company Information Table 36. GSK Business Overview Table 37. GSK Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. GSK Drugs for Asthma and COPD Product Portfolio Table 39. GSK Recent Development Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva Drugs for Asthma and COPD Product Portfolio Table 44. Teva Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Drugs for Asthma and COPD Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Drugs for Asthma and COPD Product Portfolio Table 54. Merck Recent Development Table 55. Mylan Company Information Table 56. Mylan Business Overview Table 57. Mylan Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Mylan Drugs for Asthma and COPD Product Portfolio Table 59. Mylan Recent Development Table 60. Roche Company Information Table 61. Roche Business Overview Table 62. Roche Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Roche Drugs for Asthma and COPD Product Portfolio Table 64. Roche Recent Development Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AstraZeneca Drugs for Asthma and COPD Product Portfolio Table 69. AstraZeneca Recent Development Table 70. Vertex Company Information Table 71. Vertex Business Overview Table 72. Vertex Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Vertex Drugs for Asthma and COPD Product Portfolio Table 74. Vertex Recent Development Table 75. Sumitomo Dainippon Company Information Table 76. Sumitomo Dainippon Business Overview Table 77. Sumitomo Dainippon Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio Table 79. Sumitomo Dainippon Recent Development Table 80. Chiesi Company Information Table 81. Chiesi Business Overview Table 82. Chiesi Drugs for Asthma and COPD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Chiesi Drugs for Asthma and COPD Product Portfolio Table 84. Chiesi Recent Development Table 85. Boehringer Ingelheim Company Information Table 86. Boehringer Ingelheim Business Overview Table 87. Boehringer Ingelheim Drugs for Asthma and COPD Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio Table 89. Boehringer Ingelheim Recent Development Table 90. Beximco Company Information Table 91. Beximco Business Overview Table 92. Beximco Drugs for Asthma and COPD Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Beximco Drugs for Asthma and COPD Product Portfolio Table 94. Beximco Recent Development Table 95. North America Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Drugs for Asthma and COPD Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Drugs for Asthma and COPD Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Drugs for Asthma and COPD Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Drugs for Asthma and COPD Revenue by Country (US$ Million) & (2027-2032) Table 109. China Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 110. China Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 111. China Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 112. China Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Drugs for Asthma and COPD Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Drugs for Asthma and COPD Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Drugs for Asthma and COPD Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Drugs for Asthma and COPD Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Drugs for Asthma and COPD Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Drugs for Asthma and COPD Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Drugs for Asthma and COPD Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Drugs for Asthma and COPD Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Drugs for Asthma and COPD Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Drugs for Asthma and COPD Image Figure 2. Global Drugs for Asthma and COPD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Asthma and COPD Market Size Share 2021 VS 2025 VS 2032 Figure 4. Inhalable & Nasal Spray Image Figure 5. Oral Image Figure 6. Others Image Figure 7. Global Drugs for Asthma and COPD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs for Asthma and COPD Market Size Share 2021 VS 2025 VS 2032 Figure 9. Asthma Image Figure 10. COPD Image Figure 11. Global Drugs for Asthma and COPD Market Size (US$ Million) & (2021-2032) Figure 12. Global Drugs for Asthma and COPD Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Asthma and COPD Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Asthma and COPD Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Drugs for Asthma and COPD Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Asthma and COPD Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Asthma and COPD Revenue Market Share by Type (2021-2032) Figure 19. Global Drugs for Asthma and COPD Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drugs for Asthma and COPD Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Drugs for Asthma and COPD Revenue Market Share by Application (2021-2032) Figure 22. North America Drugs for Asthma and COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Drugs for Asthma and COPD Revenue Share by Type (2021-2032) Figure 24. North America Drugs for Asthma and COPD Revenue Share by Application (2021-2032) Figure 25. North America Drugs for Asthma and COPD Revenue Share by Country (2021-2032) Figure 26. United States Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Drugs for Asthma and COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Drugs for Asthma and COPD Revenue Share by Type (2021-2032) Figure 31. Europe Drugs for Asthma and COPD Revenue Share by Application (2021-2032) Figure 32. Europe Drugs for Asthma and COPD Revenue Share by Country (2021-2032) Figure 33. Germany Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Drugs for Asthma and COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Drugs for Asthma and COPD Revenue Share by Type (2021-2032) Figure 43. China Drugs for Asthma and COPD Revenue Share by Application (2021-2032) Figure 44. Asia Drugs for Asthma and COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Drugs for Asthma and COPD Revenue Share by Type (2021-2032) Figure 46. Asia Drugs for Asthma and COPD Revenue Share by Application (2021-2032) Figure 47. Asia Drugs for Asthma and COPD Revenue Share by Region (2021-2032) Figure 48. Japan Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Drugs for Asthma and COPD Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Drugs for Asthma and COPD Revenue Share by Type (2021-2032) Figure 56. SAMEA Drugs for Asthma and COPD Revenue Share by Application (2021-2032) Figure 57. SAMEA Drugs for Asthma and COPD Revenue Share by Country (2021-2032) Figure 58. Brazil Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Drugs for Asthma and COPD Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Inhalable & Nasal Spray
  • Oral
  • Others
Applications
  • Asthma
  • COPD
Companies covered
  • GSK
  • Teva
  • Novartis
  • Merck
  • Mylan
  • Roche
  • AstraZeneca
  • Vertex
  • Sumitomo Dainippon
  • Chiesi
  • Boehringer Ingelheim
  • Beximco

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Asthma and COPD Market by Type
  3. 1.2.1 Global Drugs for Asthma and COPD Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Inhalable & Nasal Spray
  5. 1.2.3 Oral
  6. 1.2.4 Others
  7. 1.3 Drugs for Asthma and COPD Market by Application
  8. 1.3.1 Global Drugs for Asthma and COPD Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Asthma
  10. 1.3.3 COPD
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Drugs for Asthma and COPD Market Dynamics
  1. 2.1 Drugs for Asthma and COPD Industry Trends
  2. 2.2 Drugs for Asthma and COPD Industry Drivers
  3. 2.3 Drugs for Asthma and COPD Industry Opportunities and Challenges
  4. 2.4 Drugs for Asthma and COPD Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Asthma and COPD Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Asthma and COPD Growth Trends by Region
  3. 3.2.1 Global Drugs for Asthma and COPD Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Asthma and COPD Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Asthma and COPD Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Asthma and COPD Revenue by Players
  2. 4.1.1 Global Drugs for Asthma and COPD Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Asthma and COPD Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Asthma and COPD Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Asthma and COPD Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Asthma and COPD Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Asthma and COPD Players, Product Type & Application
  8. 4.5 Global Drugs for Asthma and COPD Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Asthma and COPD Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Asthma and COPD Tier 1, Tier 2, and Tier 3
5 Drugs for Asthma and COPD Market Size by Type
  1. 5.1 Global Drugs for Asthma and COPD Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Asthma and COPD Revenue Market Share by Type (2021-2032)
6 Drugs for Asthma and COPD Market Size by Application
  1. 6.1 Global Drugs for Asthma and COPD Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Asthma and COPD Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Asthma and COPD Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK Drugs for Asthma and COPD Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Drugs for Asthma and COPD Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Drugs for Asthma and COPD Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Drugs for Asthma and COPD Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Mylan
  26. 7.5.1 Mylan Company Information
  27. 7.5.2 Mylan Business Overview
  28. 7.5.3 Mylan Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Drugs for Asthma and COPD Product Portfolio
  30. 7.5.5 Mylan Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Drugs for Asthma and COPD Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 AstraZeneca
  38. 7.7.1 AstraZeneca Company Information
  39. 7.7.2 AstraZeneca Business Overview
  40. 7.7.3 AstraZeneca Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca Drugs for Asthma and COPD Product Portfolio
  42. 7.7.5 AstraZeneca Recent Developments
  43. 7.8 Vertex
  44. 7.8.1 Vertex Company Information
  45. 7.8.2 Vertex Business Overview
  46. 7.8.3 Vertex Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Vertex Drugs for Asthma and COPD Product Portfolio
  48. 7.8.5 Vertex Recent Developments
  49. 7.9 Sumitomo Dainippon
  50. 7.9.1 Sumitomo Dainippon Company Information
  51. 7.9.2 Sumitomo Dainippon Business Overview
  52. 7.9.3 Sumitomo Dainippon Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio
  54. 7.9.5 Sumitomo Dainippon Recent Developments
  55. 7.10 Chiesi
  56. 7.10.1 Chiesi Company Information
  57. 7.10.2 Chiesi Business Overview
  58. 7.10.3 Chiesi Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Chiesi Drugs for Asthma and COPD Product Portfolio
  60. 7.10.5 Chiesi Recent Developments
  61. 7.11 Boehringer Ingelheim
  62. 7.11.1 Boehringer Ingelheim Company Information
  63. 7.11.2 Boehringer Ingelheim Business Overview
  64. 7.11.3 Boehringer Ingelheim Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio
  66. 7.11.5 Boehringer Ingelheim Recent Developments
  67. 7.12 Beximco
  68. 7.12.1 Beximco Company Information
  69. 7.12.2 Beximco Business Overview
  70. 7.12.3 Beximco Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Beximco Drugs for Asthma and COPD Product Portfolio
  72. 7.12.5 Beximco Recent Developments
8 North America
  1. 8.1 North America Drugs for Asthma and COPD Revenue (2021-2032)
  2. 8.2 North America Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Asthma and COPD Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Asthma and COPD Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Asthma and COPD Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Asthma and COPD Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Asthma and COPD Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Asthma and COPD Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Asthma and COPD Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Asthma and COPD Revenue by Country
  11. 8.6.1 North America Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Asthma and COPD Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Asthma and COPD Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Asthma and COPD Revenue (2021-2032)
  2. 9.2 Europe Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Asthma and COPD Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Asthma and COPD Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Asthma and COPD Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Asthma and COPD Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Asthma and COPD Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Asthma and COPD Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Asthma and COPD Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Asthma and COPD Revenue by Country
  11. 9.6.1 Europe Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Asthma and COPD Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Asthma and COPD Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drugs for Asthma and COPD Revenue (2021-2032)
  2. 10.2 China Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Asthma and COPD Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Asthma and COPD Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Asthma and COPD Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Asthma and COPD Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Asthma and COPD Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Asthma and COPD Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Asthma and COPD Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Asthma and COPD Revenue (2021-2032)
  2. 11.2 Asia Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Asthma and COPD Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Asthma and COPD Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Asthma and COPD Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Asthma and COPD Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Asthma and COPD Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Asthma and COPD Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Asthma and COPD Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Asthma and COPD Revenue by Country
  11. 11.6.1 Asia Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Asthma and COPD Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Asthma and COPD Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Asthma and COPD Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Asthma and COPD Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Asthma and COPD Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Asthma and COPD Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Asthma and COPD Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Asthma and COPD Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Asthma and COPD Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Asthma and COPD Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Asthma and COPD Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Asthma and COPD Revenue by Country
  11. 12.6.1 SAMEA Drugs for Asthma and COPD Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Asthma and COPD Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Asthma and COPD Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst